Chronos Archive seal

Review checklist: Barbara Jordan (HR-ML030)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the McDonald classification as active primary progressive disease, the ocrelizumab choice and its screening, the vaccine timing, the re-baseline MRI without gadolinium, baclofen and mirabegron, and the decision to obtain bone density at 44.
provenance reviewnot_startedRecent-death rule: only what was reported in her life or in obituaries and reference works: the Texas State Historical Association, the House history, the Los Angeles Times obituary, a broadcaster's profile, an encyclopedia entry, a biography site, the State Cemetery and one disability-press article. The diagnosis year and the date of disclosure are uncertain and recorded as such.
safe messaging reviewnot_startedNo mental health or substance claims are made; mood screening is synthetic and below the threshold for a safety assessment. Her death is recorded in one claim as history. Disability is described without pity language, and her privacy about the diagnosis is respected in the modern plan.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Jordan died in 1996, so the rule applies. The case uses only what was reported publicly in her life or in her obituaries, and reference works that summarize those reports: the Texas State Historical Association, the House history, the Los Angeles Times obituary, a Voice of America profile, an encyclopedia entry, Biography.com, the State Cemetery, and one disability-press article that reports what she said publicly at the time about her cane. No private medical record, family account or posthumous biography is used. No sick visit is added. Her death is recorded once (CLM-0010) as history, in one plain sentence; leukemia appears nowhere in the modern episode. No claim concerns mental health or substance use; the modern mood screens are synthetic and below the threshold for a safety assessment.
  2. Private life. Nothing about her private relationships is recorded. The near-drowning at her home is mentioned only inside the conflict claim (CLM-0008), without the people involved, and is not used in the modern episode. The modern social history records that household details were not recorded at her request, and names no one.
  3. Conflicts. (1) The year of diagnosis is not stated in the sources read. Biography.com says it was later revealed that she was diagnosed around the time she left Congress (CLM-0006, graded probable); a search summary attributed a 1973 diagnosis to an encyclopedia entry, but the entry fetched did not contain it, so 1973 is not used. (2) The date of disclosure differs: after she left Congress (Voice of America), after a near-drowning dated 1994 (Ragged Edge; the Texas State Historical Association dates the near-drowning to 1988 and does not link it to the disease), or in her obituaries (encyclopedia). CLM-0008 records all three as disputed. (3) Voice of America gives January 18, 1996, as her death date; the obituary, the House history, the Texas State Historical Association and the State Cemetery give January 17, which is preferred. (4) The cane and her “bum knee” explanation rest on one posthumous article (CLM-0005, graded probable).
  4. Sources that could not be read. The New York Times obituary could not be fetched and the Smithsonian page returned an error, so neither is cited.
  5. Index age and dates. The index visit on March 2, 2026 maps to March 2, 1980, when she was 44: about a year after she left the House for the LBJ School, and after walking problems that needed a cane in her last House years (the earliest documented mobility problem). The synthetic date of birth is February 21, 1982 (shift 46 years). The chronic-care visits on March 16, April 20, June 29 and October 26, 2026, the infusions on May 4 and May 18, and the preventive visit on August 17, 2026 (age 44, so a periodic adult preventive visit) map to the same days of 1980. Past medical history includes only the cane (1978) and the diagnosis around the time she left Congress (1979). Because the diagnosis predates the index visit, the intake problem is “multiple sclerosis, course not yet classified” (G35.D, resolved at the consultation), and the classified diagnosis is recorded at the consultation.
  6. Synthetic clinical picture. The course (primary progressive, active), the MRI findings, EDSS 6.0, the timed walk, the bladder and vitamin D findings, the past steroid courses, all laboratory values and serologies, the choice of ocrelizumab, and every medication are synthetic. Primary progressive disease was chosen because the public record describes a gradual loss of mobility (cane, then walker and wheelchair) with no reported attacks, so the episode adds no invented relapse; ocrelizumab is the therapy with evidence for that course, and the enhancing lesion makes her a likely responder at 44. Qualitative results (hepatitis B serology, varicella and measles immunity, tuberculosis blood test, HIV, hepatitis C, HPV, mammogram, MRI reports, post-void residual, bone density Z-scores) appear only in note text. Height (173 cm) and weights are synthetic.
  7. Privacy and work. Her documented wish to keep the disease private shapes the modern plan: the employer letter describes functional needs without the diagnosis, and she decides who receives each letter. Reproductive plans before ocrelizumab are recorded only as discussed privately. Disability is described as part of a full working life, without pity language.
  8. Real people. No real person has a role in the modern episode. The head of the LBJ School and a University of Texas official appear only as the obituary’s sources.
  9. Preventive visit. A periodic adult preventive visit at 44 (CPT 99396 with 99497 in plain text). Judgment calls: mammography every two years from 40 (USPSTF 2024), reinforced by the ocrelizumab label; primary HPV testing; colorectal screening not until 45; lipids and A1c; bone density at 44 because of reduced mobility and earlier steroid courses, reported as Z-scores, which apply before menopause; influenza and COVID-19 vaccines deferred to October, two weeks before the next infusion; chaperones offered for the breast and pelvic examinations. Advance care planning records only her general preferences and an unnamed agent.
  10. Focused visits. The four chronic-care follow-ups (two weeks with the consultation and MRI, five weeks, four months and eight months) are documented as focused visits on the AAN 2018 disease-modifying therapy guideline, the 2017 McDonald criteria, the 2021 MAGNIMS-CMSC-NAIMS MRI consensus, the AAN 2019 immunization guideline, the ocrelizumab label, NICE NG220 for symptom care, and the CMID osteoporosis and depression monographs. One deviation is recorded instead of an invented result: the physical therapy evaluation requested at intake had not happened by the five-week visit because of a waiting list; no harm resulted (no falls, gait unchanged), the clinic escalated to a second provider, and therapy began before the four-month visit. Synthetic findings introduced: a mild first-infusion reaction, CD19 depletion after the first doses, and a re-baseline MRI with no new or enlarging lesions. The next PHQ-9 is due after the episode ends.
  11. Consultation. The multiple sclerosis neurology referral and the consultation by Kenji Watanabe, MD (a fictional consultant), on the day of the two-week visit, are S. The consultant answers the seven referral questions in line with what the record shows afterwards: primary progressive, active disease under McDonald 2017; ocrelizumab, started nine weeks after intake after hepatitis B, pneumococcal, zoster and Tdap vaccination finished two weeks earlier; monitoring of counts, immunoglobulins and liver tests before each dose; a re-baseline MRI without gadolinium at five to six months; baclofen titrated to 10 mg three times a day; mirabegron with blood pressure checks; and a written relapse and pseudo-relapse plan, which she used correctly for heat-related symptoms in the summer.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-04-20
Progress note 03 (C-CDA)
Falls, walking aids and physical therapyEvery visitMissed: the physical therapy evaluation requested at intake has not happened because of a waiting list. No harm so far: no falls and her gait is unchanged. Corrective action: the clinic asked the service today for the first available date, with a second provider if none is offered within three weeks; daily stretching and home exercises meanwhile

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-16
Progress note 02 (C-CDA)
ReferralFalls, walking aids and physical therapyOrderedNo falls; physical therapy evaluation requested at intake, first appointment awaited
2026-08-17
Progress note 05 (C-CDA)
PreventionBreast cancer screeningOrderedMammogram every two years from 40; no previous mammogram on file; ordered today, with the ocrelizumab label's advice to follow standard screening

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-0225-hydroxyvitamin D17 ng/mL (low)Low
2026-06-29CD19 B cells (absolute)3 /uL (low)Low